Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Blood–brain barrier and blood–retinal barrier disruption to 14C-sucrose

From: Disruption of the hippocampal and hypothalamic blood–brain barrier in a diet-induced obese model of type II diabetes: prevention and treatment by the mitochondrial carbonic anhydrase inhibitor, topiramate

Region Prevention Efficacy
LF LF TPM HF HF TPM LF LF TPM HF HF TPM
Whole brain 9.704 ± 2.586 12.86 ± 2.869 10.67 ± 3.386 11.59 ± 1.884 7.936 ± 3.422 7.568 ± 1.839 9.584 ± 3.593 7.978 ± 2.508
Retina 161.2 ± 38.52 153.4 ± 52.74 161.3 ± 30.87 197.2 ± 42.03 138.1 ± 27.51 166.2 ± 20.10 184.1 ± 25.68a 184.1 ± 31.34a
Vitreous humor 55.53 ± 18.10 51.12 ± 15.29 48.40 ± 13.74 65.70 ± 16.15 40.69 ± 1.939 59.70 ± 17.77 55.29 ± 14.97 60.10 ± 15.10
Olfactory bulb 18.58 ± 6.127 26.77 ± 14.24 23.47 ± 11.87 25.26 ± 13.44 15.74 ± 2.848 17.04 ± 4.781 17.38 ± 4.052 16.57 ± 2.744
Striatum 9.636 ± 2.148 9.643 ± 1.677 11.16 ± 3.700 11.58 ± 2.340 7.375 ± 2.047 6.979 ± 1.390 6.956 ± 1.072 7.978 ± 2.517
Frontal cortex 9.605 ± 3.311 11.22 ± 3.896 9.428 ± 4.862 11.09 ± 2.339 5.973 ± 1.285 6.161 ± 0.789 6.422 ± 1.225 6.029 ± 0.578
Hypothalamus 21.42 ± 6.130 24.46 ± 6.736 50.96 ± 27.71a 23.12 ± 4.293b 10.50 ± 2.365 12.04 ± 2.413 16.85 ± 3.627a 15.51 ± 2.898a
Hippocampus 7.753 ± 1.220 9.704 ± 0.950 11.73 ± 3.021a 12.06 ± 2.466a 6.070 ± 1.327 7.029 ± 1.186 8.580 ± 1.862a 6.594 ± 0.875b
Thalamus 10.05 ± 2.202 10.41 ± 2.625 8.770 ± 3.176 10.54 ± 2.138 7.135 ± 0.815 7.107 ± 1.435 6.421 ± 0.632 6.402 ± 0.674
Parietal cortex 8.412 ± 2.212 10.78 ± 3.310 9.458 ± 3.105 10.79 ± 2.743 6.235 ± 1.416 6.235 ± 1.369 6.413 ± 1.840 5.763 ± 0.827
Occipital cortex 9.764 ± 2.013 12.10 ± 3.037 10.31 ± 2.756 10.53 ± 2.759 7.815 ± 1.858 6.898 ± 1.683 7.451 ± 1.669 7.581 ± 1.401
Cerebellum 8.223 ± 2.127 10.12 ± 2.517 9.427 ± 3.065 10.20 ± 1.709 6.832 ± 1.551 6.890 ± 1.142 8.018 ± 3.389 6.654 ± 1.005
Midbrain 8.889 ± 3.054 13.09 ± 5.116 10.51 ± 3.445 12.87 ± 2.407 7.309 ± 1.458 7.321 ± 1.706 7.913 ± 1.991 6.774 ± 1.046
Pons-medulla 11.95 ± 4.057 13.90 ± 3.024 11.78 ± 4.316 14.71 ± 3.700 9.642 ± 1.321 10.92 ± 2.397 11.92 ± 6.198 10.24 ± 2.984
  1. 14C-sucrose was used to assess permeability after TPM treatment
  2. Units, µL/g. Values are expressed as mean ± SD. Significance was determined by a one-way analysis of variance followed by Newman–Keuls post-test
  3. LF low-fat diet + saline group, LF TPM low-fat diet + topiramate group, HF high-fat diet + saline group, HF TPM high-fat diet + topiramate group
  4. aSignificance in comparison to LF control
  5. bSignificance in comparison to HF